Brief: Immuneering Advances Towards Dosing First Patient In Phase 3 Atebimetinib Trial
17/12/2025 21:08
Dec 17 (Reuters) - Immuneering Corp IMRX.O: IMMUNEERING ADVANCES TOWARDS DOSING FIRST PATIENT IN PHASE 3 ATEBIMETINIB TRIAL FOR FIRST-LINE METASTATIC PANCREATIC CANCER PATIENTS, SECURING ALIGNMENT WITH FDA AND EMA IMMUNEERING EXPECTS TO DOSE FIRST PATIENT IN GLOBAL PHASE 3 REGISTRATIONAL TRIAL, MAPKEEPER 301, IN MID-2026 IMMUNEERING: EXPECTS TO SHARE TOPLINE RESULTS FROM TRIAL IN MID-2028 Source text: ID:nGNX9y1Bcm Further company coverage: IMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuneering
See all newsImmuneering expects cash runway to fund operations into 2029
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences